AMENDMENT #1 TO THE LICENSE AGREEMENTThe License Agreement • May 9th, 2012 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances)
This Amendment #1 to the AGREEMENT (“Amendment #1) is made by and between PAION Holdings UK Ltd (Company Number SC 166791) (“Paion” ) whose principal place of business is at Compass House, Vision Park, Chivers Way, Histon, Cambridge CB24 9ZR, UK, and Acorda Therapeutics, Inc. (“Acorda” or “LICENSEE”), a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 15 Skyline Drive, Hawthorne, NY 10532.
AGREEMENT AND PLAN OF MERGER among: Acorda Therapeutics, Inc., a Delaware corporation; ATI Development Corp., a Delaware corporation; Neuronex, Inc., a Delaware corporation; and Moise A. Khayrallah as the Stockholders’ Representative Dated as of...Agreement and Plan of Merger • May 9th, 2012 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
This Agreement and Plan of Merger (“Agreement”) is made and entered into as of February 15, 2012, by and among: Acorda Therapeutics, Inc., a Delaware corporation (“Parent”); ATI Development Corp., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”); Neuronex, Inc., a Delaware corporation (the “Company”); and Moise A. Khayrallah, Ph.D., a resident of North Carolina, solely as the Stockholders’ Representative as set forth herein. Certain capitalized terms used in this Agreement are defined in Exhibit A.
